COLLABORATION AGREEMENTS (Tables)

9 Months Ended

Sep. 30, 2012

Schedule Of Collaboration Revenue

Collaboration revenue for the three and nine months ended September 30, 2012 and 2011 was as follows:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2012		2011		2012		2011
Collaboration revenue:
Attributable to U.S. XTANDI sales	$	7,056	$	—	$	7,056	$	—
Attributable to ex-U.S. XTANDI sales		—		—		—		—
Attributable to up-front and milestone payments		57,742		14,940		137,479		45,448
Total collaboration revenue	$	64,798	$	14,940	$	144,535	$	45,448

Schedule Of Collaboration Revenue Attributable To Sales

Collaboration revenue attributable to U.S. XTANDI sales for the three and nine months ended September 30, 2012 was as follows:

	Three Months Ended September 30, 2012			Nine Months Ended September 30, 2012
Net U.S. sales (as reported by Astellas)	$	14,112		$	14,112
Shared U.S. development and commercialization costs		(41,928	)		(41,928	)
Pre-tax U.S. profit (loss)	$	(27,816	)	$	(27,816	)
Medivation’s share of pre-tax U.S. profit (loss)	$	(13,908	)	$	(13,908	)
Reimbursement of Medivation’s share of shared U.S. costs		20,964			20,964
Collaboration revenue attributable to U.S. XTANDI sales	$	7,056		$	7,056

Collaboration Revenue Attributable To Up-Front And Milestone Payments

Collaboration revenue attributable to up-front and milestone payments for the three and nine months ended September 30, 2012 and 2011 was as follows:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2012		2011		2012		2011
Collaboration revenue attributable to up-front and milestone payments:
From Astellas	$	52,256	$	5,936	$	65,449	$	18,436
From Pfizer		5,486		9,004		72,030		27,012
Total collaboration revenue attributable to up-front and milestone payments	$	57,742	$	14,940	$	137,479	$	45,448

Deferred Revenue

Deferred revenue consisted of the following:

	September 30, 2012		December 31, 2011
Current portion:
Deferred revenue from Astellas	$	29,024	$	23,747
Deferred revenue from Pfizer		—		36,015
Total	$	29,024	$	59,762
Long-term portion:
Deferred revenue from Astellas	$	21,768	$	47,494
Deferred revenue from Pfizer		—		36,015
Total	$	21,768	$	83,509

Development And Commercialization Cost-Sharing Payments

The following table summarizes the reductions in R&D related to cost-sharing payments for the periods presented:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2012		2011		2012		2011
Development cost-sharing payments from Astellas	$	11,003	$	11,480	$	39,131	$	32,593
Development cost-sharing payments from Pfizer		51		2,484		1,740		10,387
Total	$	11,054	$	13,964	$	40,871	$	42,980

The following table summarizes the (increases) reductions in SG&A related to cost-sharing payments for the periods presented:

	Three Months Ended September 30,						Nine Months Ended September 30,
	2012			2011			2012			2011
Commercialization cost-sharing payments (to) from Astellas	$	(1,187	)	$	176		$	(1,857	)	$	634
Commercialization cost-sharing payments (to) from Pfizer		—			(3	)		9			33
Total	$	(1,187	)	$	173		$	(1,848	)	$	667